Safety and Efficacy of PD‐1/PD‐L1 inhibitors combined with radiotherapy in patients with non‐small‐cell lung cancer: a systematic review and meta‐analysis

BACKGROUND: A combination of programmed cell death protein‐1 (PD‐1)/programmed cell death ligand‐1 (PD‐L1) inhibitors and radiotherapy (RT) is increasingly being used to treat non‐small‐cell lung cancer (NSCLC). However, the safety and efficacy of this approach remains controversial. We performed a...

Descripción completa

Detalles Bibliográficos
Autores principales: Geng, Yichao, Zhang, Qiuning, Feng, Shuangwu, Li, Chengcheng, Wang, Lina, Zhao, Xueshan, Yang, Zhen, Li, Zheng, Luo, Hongtao, Liu, Ruifeng, Lu, Bing, Wang, Xiaohu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926021/
https://www.ncbi.nlm.nih.gov/pubmed/33465302
http://dx.doi.org/10.1002/cam4.3718

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926021/
https://www.ncbi.nlm.nih.gov/pubmed/33465302
http://dx.doi.org/10.1002/cam4.3718

Ejemplares similares